News Posts List
Dr. Pal Discusses the Role of PD-L1 in Metastatic RCC
06/28/2018
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma (RCC). One of the biggest unanswered questions in the frontline setting of metastatic RCC is the role of PD-L1. Pal says that there is more to the PD-L1 story, particularly considering the findings of the CheckMate-214 trial. There was a clear difference in clinical outcomes for patients who were PD-L1–positive versus PD-L1–negative, Pal explains. Whether that is clinically applicable is not established.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership
06/27/2018
Ipsen, a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer Science (IACS).
Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA
06/27/2018
Bristol-Myers Squibb Company BMY announced that the FDA accepted its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo for the indication first-line advanced non-small cell lung cancer (NSCLC) in patients with tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb). The FDA set an action date of Feb 20, 2019.
Pembrolizumab Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy
06/13/2018
KEYNOTE-427 is a single-arm, open-label, non-randomized, multi-cohort, Phase 2 study evaluating the safety and efficacy of KEYTRUDA as monotherapy in patients with advanced RCC who have not received prior systemic therapy.
California emergency room use has actually risen after the passage of Obamacare
06/13/2018
Emergency department visits, including those that resulted in hospital admissions, grew an average 4 percent every year from 2010 to 2016.
More Frequent Use of Partial Nephrectomy May Benefit Kidney Cancer Patients
06/13/2018
To evaluate trends in the use of partial nephrectomy in the United States, researchers collected information about more than 48,000 patients with non-metastatic kidney cancer treated between 1998 and 2007.
2018 Young Investigator Award Winners
05/05/2018
The Kidney Cancer Association has announced the winners of its annual Young Investigator Award (YIA). The award provides funding to promising doctors to pursue careers in kidney cancer research.
FDA approves combination for advanced renal cell carcinoma
04/17/2018
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.
JAMA: Payments influence oncologist prescribing
04/17/2018
Lead study author Aaron Mitchell said they also found prescriptions increased as the amount of money physicians received went up. Payments for research, by contrast, were not associated with statistically significant differences in prescribing.
First step to kidney cancer may occur in childhood
04/17/2018
A single damaged cell may be all it takes to trigger aggressive and terminal kidney cancer almost a lifetime after the first step towards the disease is taken.
News Feed